Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf263 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Isabelle Rydén und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H.,…. Hauptthemen laut MEDLINE: Glioma, Isocitrate Dehydrogenase, Brain Neoplasms, Mutation. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish government and the county councils, Swedish Research Council, The Swedish Society of Medicine.
Abstract (Originalsprache)
Background
Management of isocitrate dehydrogenase (IDH) mutated gliomas is multidisciplinary and current guidelines support early multimodal treatment. The effects of this treatment approach on cognition are less studied. We aimed to study changes in cognitive functioning the first year following treatment in these patients and explore predictors of cognitive deterioration.
Methods
Patients with a first-time diagnosis of IDH mutated glioma were neuropsychologically assessed before and one year after surgery. Results were compared to published norms, and impairment defined as z <−1.645. Matched controls were assessed at corresponding times, and reliable change indices (RCIs) were calculated to account for practice effects. Logistic regression models investigated predictors for cognitive declines. Tumor locations for declined versus non-declined patients were visualized using heatmaps.
Results
Of the 127 included patients, 104 underwent multi-modal treatment. Pre-operative impairments ranged from 3% to 24%, depending on the specific test. Cognitive declines according to RCI domains were largest in tests of executive functioning (24%), learning/memory (23%), and language (21%). Tests of inhibition/flexibility (32%), naming speed (29%), verbal memory (28%), object naming (28%), and verbal fluency (22%) showed the largest proportions of declines. Regression models revealed that older age and chemoradiotherapy predicted declines in specific domains as well as in individual tests (P < 0.05).
Conclusions
Significant changes occurred in several cognitive domains after guideline-based treatment. Older age and chemoradiotherapy increased the risk of cognitive declines one year after surgery, but to which extent the deficits are persistent or progressing remains unknown.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).
- Department of Neurology, Sahlgrenska University Hospital, Gothenburg (I.R., A.S.).
- Section of Neurosurgery, Department of Neuroscience, Uppsala University, Uppsala (F.L.).
- Rehabilitation and Pain Centre, Uppsala University Hospital, Uppsala (Å.A.M.).
- Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg (L.C., A.S.J.).
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg (M.B.).
ORCID-Profile: Isabelle Rydén, Francesco Latini, Per Hellström, Alice Neimantaite, Dima Harba, Louise Carstam, Malin Blomstrand, Maria Zetterling, Anja Smits, Asgeir S Jakola
Förderung
- Swedish government and the county councils
- Swedish Research Council
- The Swedish Society of Medicine
- Göteborg Foundation for Neurological Research
- Swedish Neuropsychological Society
- Anna-Lisa and Bror Björnssons stiftelse
- Amlövs stiftelse
- Jubileumsklinikens Cancerfond
Zitieren
APA
Rydén, I., Latini, F., Alberius Munkhammar, Å., Hellström, P., Neimantaite, A., Lycett, A., Harba, D., Carstam, L., Blomstrand, M., Zetterling, M., Smits, A., & Jakola, A. S. (2025). Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf263
Vancouver
Rydén I, Latini F, Alberius Munkhammar Å, Hellström P, Neimantaite A, Lycett A, et al. Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf263
BibTeX
@article{Rydn2025,
author = {Rydén, Isabelle and Latini, Francesco and Alberius Munkhammar, Åsa and Hellström, Per and Neimantaite, Alice and Lycett, Andrew and Harba, Dima and Carstam, Louise and Blomstrand, Malin and Zetterling, Maria and Smits, Anja and Jakola, Asgeir S},
title = {Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf263}
}
EUVIMED